Generic Competition and Negative Foreign Currency Translation Hold Back Merck's Q4 Results

Merck also announced it's "exploring strategic alternatives" for its animal health and consumer care businesses to determine if value can be unlocked for shareholders.

Feb 5, 2014 at 12:43PM

Pharmaceutical giant Merck (NYSE:MRK) found the sledding tough this brisk winter morning after reporting fourth-quarter results that delivered a slight increase in adjusted EPS, but also a decline in sales for a number of key drugs.

For the fourth quarter, Merck reported revenue of $11.32 billion, a 3.6% decline from the $11.74 billion reported in the year-ago period, as its adjusted profit per share improved modestly to $0.88 from $0.83. Including one-time costs, Merck's GAAP profits fell 14% to $0.26 per share. Negative foreign currency translation was responsible for a three-percentage-point knock against Merck's quarterly revenue decline.

The real story for Merck's fourth-quarter report was its struggle against patent losses on key drugs that weighed down its final results.

The loss of patent exclusivity on Singulair (which saw a 38% decline in sales), Temodar, and Maxalt hampered any chance of revenue growth, while top-selling diabetes drug Januvia struggled to a 1% revenue decline, totaling $1.12 billion in sales for the quarter.

Offsetting this weakness were inflammatory disease drugs Remicade and SImponi, which, combined, saw sales improve 19% to $766 million as Simponi's launch in other countries meaningfully affected sales growth. HIV-therapy Isentress also delivered an impressive 16% increase in sales to $442 million. Emerging market growth was another bright spot for Merck, with sales growth of 2% (that includes a negative 6% impact from foreign currency translation) as vaccine, acute care, and diabetes product sales found traction.

The company also announced that it's "exploring strategic alternatives" for its animal health and consumer care businesses to determine if value can be unlocked for shareholders. A decision on whether any action will be taken should be reached this year.

Looking ahead to 2014, Merck is forecasting full-year revenue of $42.4 billion to $43.2 billion, representing a decline of 3% year over year at the midpoint, with adjusted EPS projected in the $3.35 to $3.53 range, which is fairly consistent with the adjusted $3.49 in EPS it reported in fiscal 2013.

link

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers